If you think there has been an overdose, call your poison control center or get medical care right away. We comply with the HONcode standard for trustworthy health information - Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (February 2016) NICE TA385. This guidance should be used with … This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. All drugs may cause side effects. Read all information given to you. Data sources include IBM Watson Micromedex (updated 2 Sep 2020), Cerner Multum™ (updated 1 … help if any of these side effects or any other side effects bother you or do not go away: For the latest FDA MedWatch alerts, Audience: Endocrinologists, cardiologists, other healthcare professionals, patientsFDA anticipates receiving a final SEAS study report in about 3 months and the Agency's review and evaluation of the clinical trial data and other relevant information should take approximately 6 months. FDA will communicate its conclusions and recommendations at that time. National funding/access decisions. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.
This means that the liver has to increase its efforts to take more cholesterol out of the blood.
... Rebetol in combination with interferon alfa-2b. 4.4 Special warnings and precautions for use. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. You may report side effects to the FDA at 1-800-332-1088. Follow all instructions closely. Manufacturer advises avoid—present in milk in animalstudies. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. Ezetimibe is indicated to reduce the risk of cardiovascular events (see section 5.1) in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin. Healthcare professionals and caregivers should continue to monitor patients taking Vytorin and report side effects from the use of this drug to the Agency.Audience: Cardiovascular healthcare professionals and patientsGavreto (pralsetinib) is an oral selective RET kinase inhibitor for the...Onureg (azacitidine) is a nucleoside metabolic inhibitor indicated for the...Qdolo (tramadol hydrochloride) is an opioid agonist indicated in adults for ...Xaracoll (bupivacaine hydrochloride) is a fully bioresorbable collagen implant...The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Hepatic impairment.
Manufacturer advises avoid in moderate to severe impairment.
The FDA Alert(s) below may be specifically about ezetimibe or relate to a group or class of drugs which include ezetimibe.MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Learn about side effects, warnings, dosage, and more. As a result less cholesterol is taken to the liver for re-cycling. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. Ezetimibe is a “cholesterol absorption inhibitor” which means it works by partially blocking the reabsorption of cholesterol (from the diet and from bile) in the small intestine. Zetia is a lipid-lowering compound used to treat high cholesterol.Common side effects of ezetimibe include diarrhea, abdominal pain, back pain, joint pain, muscle aches, and sinus infection ().. Serious side effects of ezetimibe include hypersensitivity reactions (including angioedema - swelling of the skin and underlying tissues of the head and neck - that can be life … NICE ta385. doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: Multiple-dose pharmacokinetic properties for Rebetol capsules and interferon alfa-2b in children and adolescents with chronic hepatitis C between 5 and 16 years of age are summarized in Table 15.
The FDA Alert (s) below may be specifically about ezetimibe or relate to a group or class of drugs which include ezetimibe.
Available for Android and iOS devices.